A Phase 1 interventional study of TQB3616 Capsule in Recurrent/Metastatic Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-25.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing culmerciclib in Breast Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. culmerciclib · Breast Neoplasms.
Among the 15 studies testing culmerciclib in Breast Neoplasms, this one is the 14th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 1, and was the 3rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →8 of the 15 studies testing culmerciclib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
Sun Yat-sen University · Sites in China
Ages 18+ · Women only
Fudan University · Sites in China
Ages 18–75 · Women only
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Shengjing Hospital · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 40 across the 15 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 7 most frequent:
This study is registered under Chia Tai Tianqing Pharmaceutical Group Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited: 11 open now, 16 under way, 8 of them phase 3. Of 8 finished, 0 (0%) have results posted.
Among the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, this one is the 26th largest by enrollment, is one of 2 that started in 2021, is one of 8 in phase 1, and was the 6th registered.
Sino Biopharmaceutical Limited’s Breast Neoplasms studies by the year they started, since 2012.
1 of the studies testing culmerciclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing culmerciclib in Breast Neoplasms, from their registry updates:
Among Sino Biopharmaceutical Limited’s 28 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
TQB3616 capsule is a small molecule oral drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., which inhibits cyclin-dependent kinases 4 and 6 (CDK4/6). Its main mechanism of action is to inhibit the proliferation of tumor cells by reducing the phosphorylation level of retinoblastoma protein (Rb) in cancer cells and blocking the progression of cells from G1 phase to S phase. This study is a randomized, open-label, single-center, two-period, two-crossover phase I clinical trial to assess the effect of food on the pharmacokinetics of TQB3616 capsules in healthy adult subjects, to evaluate the effect of food on the pharmacokinetics of TQB3616 capsules after oral administration in healthy adult Chinese subjects and to observe the safety of TQB3616 capsules after single oral administration in healthy subjects.Each subject will be randomly assigned to one of two groups (group A and B). A total of 16 subjects were enrolled, all taking TQB3616 capsules 180mg, including 8 subjects in group A and 8 subjects in group B. The study included screening period, randomization, first cycle, washout period and second cycle. The first cycle and second cycle each contained 3 return visits. 18 pharmacokinetic samples were collected every cycle for pharmacokinetic index analysis. Vital signs, physical examinations, 12-lead electrocardiograms, clinical laboratory tests, adverse events, drug combination and non-drug therapy information were collected during the study to ensure the safety of the subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in Arm A will take TQB3616 capsules under fasting and fed state in Cycle 1 and Cycle 2, respectively
Drug: TQB3616 Capsule
Subjects in Arm B will take TQB3616 capsules in Cycle 1 and Cycle 2 under fasting state, respectively
Drug: TQB3616 Capsule
It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
Peak concentration(Cmax)
Maximum plasma drug concentration
Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Area under the time-concentration curve from 0 to t hours after drug administration(AUC0-t))
Area under the plasma concentration-time curve from the time of first dose to the time of the last measurable concentration
Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Area under the time-concentration curve from 0 to infinity after drug administration(AUC0-∞)
Area under the plasma concentration-time curve from the time of first dosing extrapolated to infinity
Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Time to peak(Tmax)
Time to reach maximum (peak) plasma concentration following drug administration
Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Elimination half-life(t1/2)
Elimination half-life (to be used in one-or non-compartmental model)
Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Apparent volume of distribution(Vd/F)
Apparent volume of distribution after non-intravenous administration
Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Apparent clearance(CL/F)
Apparent total clearance of the drug from plasma after oral administration
Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Bioavailability(F)
Bioavailability (systemic availability of the administered dose)
Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Elimination rate constant (λz)
Terminal disposition rate constant/terminal rate constant
Time frame: The first and second cycles before administration, 1, 2, 3, 4, 5, 5.5, 6, 6.5, 7, 8, 12, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Body temperature
Abnormal body temperature
Time frame: The first and second cycles before adminisyration, 1, 2, 6, 8, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Pulse
Abnormal pulse
Time frame: The first and second cycles before adminisyration, 1, 2, 6, 8, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Blood pressure
Abnormal blood pressure
Time frame: The first and second cycles before adminisyration, 1, 2, 6, 8, 24, 48, 72, 120, 168 and 264 hours after administration (each cycle is 12 days)
Physical examination
The doctor percusses, looks, and questions the subject
Time frame: After the end of the first cycle and the second cycle (each cycle is 12 days)
Electrocardiogram QT interval
Safety Checks
Time frame: After the end of the first cycle and the second cycle (each cycle is 12 days)
Adverse Events
Monitor the safety indicators of subjects during the trial
Time frame: Up to 31 days (each cycle is 12 days)
Ran from Jul 2021 to primary completion in Aug 2021, 1 month.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 1 month is below that.
Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Culmerciclib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →